S
StemoniX
StemoniX is revolutionizing the production, growth, and development of stem cell and stem cell technologies
About StemoniX
StemoniX specializes in creating human organoid models and advanced analytical algorithms to accelerate drug discovery and reduce development costs. The company partners with leading biopharma, academic, and government institutions to provide functional models, expert services, and actionable results. StemoniX's core offerings include off-the-shelf and custom disease models, as well as their Assay AnalytiX platform, which combines human biology and artificial intelligence to deliver deeper insights and faster returns from experiments. The company serves clients in the pharmaceutical and biotechnology sectors, focusing on improving the efficiency and effectiveness of drug development processes. StemoniX generates revenue through the sale of its organoid models, analytical services, and custom research solutions.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Maple Grove, United States
- Employees
- 3
- Open positions
- None listed
- Dealroom signal
- 88.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Cardiology and cardiovascular, Stem Cells, Health Diagnostics, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
- Investment activity
- 1 company, latest Mar 2021
- Capital deployed
- —
- Preferred round
- MERGER
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| MERGER✓Other financing | Mar 2021 | $0 | — | Cancer Genetics (Vyant Bio) | — |
| OtherOther financing | Aug 2020 | $0 | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for StemoniX is 380 monthly website visits, down 35.6% over the last three months. StemoniX's team grew 200% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 NcardiaDrug discovery and development stem cell technology |
Leiden, Netherlands | Operational | 42 | $76M | $240M |
 MettleAILeveraging ML/AI to predict substance abuse relapse before it happens |
Toronto, Canada | Operational | |||
 Nostos GenomicsPartners with genetic labs to transform data into insights and deliver faster, clearer diagnoses for genetic diseases |
Berlin, Germany | Acquired | |||
 Lipigon PharmaceuticalsSpecialized in fat metabolism and develops new blood lipids |
Umeå kommun, Sweden | Operational | |||
 CardioDXCardiovascular genomic diagnostics |
Redwood City, United States | Operational | |||
 UltromicsAI-powered echocardiogram analysis for heart failure detection. |
Oxford, United Kingdom | Operational | |||
 Morphogen-IXEngineered protein therapeutics for pulmonary arterial hypertension |
Babraham, United Kingdom | Acquired | |||
 ABIONYXDeveloping of novel therapies for the treatment of cardiovascular and metabolic diseases |
Balma, France | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Exponential
Brightstone Venture Capital
Other known investors7 additional known investors
Cancer Genetics (Vyant Bio)
Alumni Ventures
Cavendish Global
Cavendish Impact Capital
Crescent Ridge
EvoNexus
For Good Ventures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about StemoniX on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See StemoniX’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.